Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Jan 14, 2020 6:30am

177 Views

Post# 30549812

RE:RE:RE:RE:here we go

"No-brainer approval to me."

I'm not sure if you are referring to application for breakthrough therapy status or NDA/MAA approval with FDA/EMA. Keep in mind these SGLT2i and/or DPP4i are still a post-hoc analysis, and not pre-specified. Post-hocs are never "no brainers." Although not impossible to get FDA/EMA approval w/o another trial, the more probable scenario would be further clinical development prior to FDA/EMA approval.

BDAZ

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload